These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26996311)

  • 41. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice.
    Filippi A; Bignamini AA; Sessa E; Samani F; Mazzaglia G
    Stroke; 2003 Apr; 34(4):1010-4. PubMed ID: 12637698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Socioeconomic inequality in medication persistence in primary and secondary prevention of coronary heart disease - A population-wide electronic cohort study.
    King W; Lacey A; White J; Farewell D; Dunstan F; Fone D
    PLoS One; 2018; 13(3):e0194081. PubMed ID: 29522561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary prevention of atherothrombotic cerebrovascular events.
    Paciaroni M
    Curr Vasc Pharmacol; 2014 May; 12(3):365-72. PubMed ID: 24846225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood pressure level and outcomes in adults aged 65 and older with prior ischemic stroke.
    Kaplan RC; Tirschwell DL; Longstreth WT; Manolio TA; Heckbert SR; LeValley AJ; Lefkowitz D; El-Saed A; Psaty BM
    J Am Geriatr Soc; 2006 Sep; 54(9):1309-16. PubMed ID: 16970636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
    Zanchetti A; Liu L; Mancia G; Parati G; Grassi G; Stramba-Badiale M; Silani V; Bilo G; Corrao G; Zambon A; Scotti L; Zhang X; Wang H; Zhang Y; Zhang X; Guan TR; Berge E; Redon J; Narkiewicz K; Dominiczak A; Nilsson P; Viigimaa M; Laurent S; Agabiti-Rosei E; Wu Z; Zhu D; Rodicio JL; Ruilope LM; Martell-Claros N; Pinto F; Schmieder RE; Burnier M; Banach M; Cifkova R; Farsang C; Konradi A; Lazareva I; Sirenko Y; Dorobantu M; Postadzhiyan A; Accetto R; Jelakovic B; Lovic D; Manolis AJ; Stylianou P; Erdine S; Dicker D; Wei G; Xu C; Xie H; Coca A; O'Brien J; Ford G
    J Hypertens; 2014 Sep; 32(9):1888-97. PubMed ID: 24979303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.
    Emberson JR; Whincup PH; Lawlor DA; Montaner D; Ebrahim S
    Heart; 2005 Apr; 91(4):451-5. PubMed ID: 15772196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effects of secondary prevention on cognitive function in stroke patients.
    Douiri A; McKevitt C; Emmett ES; Rudd AG; Wolfe CD
    Circulation; 2013 Sep; 128(12):1341-8. PubMed ID: 23935013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts.
    Rivier CA; Acosta JN; Leasure AC; Forman R; Sharma R; de Havenon A; Spatz ES; Inzucchi SE; Kernan WN; Falcone GJ; Sheth KN
    J Am Heart Assoc; 2024 May; 13(9):e033322. PubMed ID: 38639369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013.
    Kotseva K; De Bacquer D; Jennings C; Gyberg V; De Backer G; Rydén L; Amouyel P; Bruthans J; Cifkova R; Deckers JW; De Sutter J; Fraz Z; Graham I; Keber I; Lehto S; Moore D; Pajak A; Wood D;
    Glob Heart; 2017 Dec; 12(4):315-322.e3. PubMed ID: 26994643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Secondary prevention of coronary heart disease. Results from EuroASPIRE I and II in the region of Münster, Germany].
    Heidrich J; Liese AD; Kalic M; Winter-Enbergs A; Wellmann J; Roeder N; Kerber S; Breithardt G; Scheld HH; Kleine-Katthöfer P; Keil U
    Dtsch Med Wochenschr; 2002 Mar; 127(13):667-72. PubMed ID: 11928058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Changes in the prevalence of statin use in Germany - findings from national health interview and examination surveys 1997-1999 and 2008-2011].
    Knopf HC; Busch MA; Du Y; Truthmann J; Schienkiewitz A; Scheidt-Nave C
    Z Evid Fortbild Qual Gesundhwes; 2017 May; 122():22-31. PubMed ID: 28511896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
    Giverhaug T; Bruland C; Trovik T
    Pharm World Sci; 2005 Dec; 27(6):472-4. PubMed ID: 16341957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys.
    Pajak A; Jankowski P; Kawecka-Jaszcz K; Surowiec S; Wolfshaut R; Loster M; Batko K; Badacz L; Dubiel JS; Grodecki J; Grodzicki T; Maciejewicz J; Mirek-Bryniarska E; Piotrowski W; Smielak-Korombel W; Tracz W
    Kardiol Pol; 2009 Dec; 67(12):1353-9. PubMed ID: 20054766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study.
    Sjölander M; Eriksson M; Glader EL
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):911-9. PubMed ID: 22069216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins for stroke prevention: disappointment and hope.
    Amarenco P; Tonkin AM
    Circulation; 2004 Jun; 109(23 Suppl 1):III44-9. PubMed ID: 15198966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimal combination secondary prevention drug treatment and stroke outcomes.
    Park JH; Ovbiagele B
    Neurology; 2015 Jan; 84(1):50-6. PubMed ID: 25411440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary Prevention Three and Six Years after Stroke Using the French National Insurance Healthcare System Database.
    Mechtouff L; Haesebaert J; Viprey M; Tainturier V; Termoz A; Porthault-Chatard S; David JS; Derex L; Nighoghossian N; Schott AM
    Eur Neurol; 2018; 79(5-6):272-280. PubMed ID: 29758555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins after recent stroke reduces recurrence and improves survival in an aging Mediterranean population without known coronary heart disease.
    Sicras-Mainar A; Planas-Comes A; Frias-Garrido X; Navarro-Artieda R; de Salas-Cansado M; Rejas-Gutiérrez J
    J Clin Pharm Ther; 2012 Aug; 37(4):441-7. PubMed ID: 22059532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.